Two randomized phase II trials of Osimertinib with or without SRS for the treatment of EGFR mutant NSCLC with BM (NCT03497767 and NCT03769103) are about to begin, and we are looking forward to their results. Here, EGFR is linked to non-small cell lung carcinoma.